A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
PHASE1
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer i...
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
PHASE1
Multiple myeloma (MM) is a plasma cell disease characterized by the growth ...
Status
Active Not Recruiting
Location
University of Arkansas for Medical Sciences /ID# 243096
Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma
PHASE1
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer i...